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See related research by Ostermann et al. http://www.ccforum.com/content/14/3/R419Premature clotting of the circuit is the most common
reason for unplanned interruptions in renal replacement
therapy (RRT) and discrepancies between the prescribed
and delivered dose of RRT [1]. The recent guideline
from the Kidney Disease Improving Global Outcomes
(KDIGO) working group recommended citrate as the
first-line anticoagulant for continuous renal replacement
therapy (CRRT) [2]. For patients with contraindications
to citrate, either unfractionated or low molecular weight
heparin was recommended.
Worldwide, unfractionated heparin is the most com-
monly used anticoagulant to maintain circuit patency
[1]. The potential risks including bleeding and heparin-
induced thrombocytopenia are well known. In 2010, we
designed an algorithm to enable the nursing staff to
manage heparin during CRRT effectively and safely [3].
In response to new knowledge and changes in clinical
practice, we have revised the algorithm (Fig. 1).
The main principles of the algorithm are maintained
as follows:
1. The indication for heparin should be reviewed daily.
Heparin should be avoided in patients with an
increased bleeding risk.
2. Unfractionated heparin is administered via the
circuit unless the patient needs systemic
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4. Dosing of heparin is “individualised” depending on
the patient’s risk of bleeding and previous circuit life.
5. There is no target activated partial thromboplastin
time ratio (APTTr) but APTTr ≤2 is maintained to
prevent overanticoagulation.
6. Nonpharmacological methods should be considered
regularly to maintain circuit patency.
The main changes to the algorithm are the following:
1. We previously suggested adding heparin to the
circuit priming solution before the blood is in
contact with plastic surfaces to coat the surfaces of
the filter membrane and circuit tubing. It has since
been brought to our attention that a randomised
controlled cross-over study in 11 patients on CRRT
showed no beneficial effect of heparin rinse on the
thrombogenicity of the circuit, complement activation
or blood leukocyte counts [4]. Therefore, instead of
using 10,000 IU heparin in 1 l of 0.9 % saline to
prime a circuit with total volume ~270 ml, we
suggest administering a bolus of 2500 IU heparin
on connection.
2. Following the withdrawal of activated protein C
[5], a reference to this drug has been removed
from the algorithm.is distributed under the terms of the Creative Commons Attribution 4.0
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Fig. 1 Algorithm for heparin anticoagulation during CRRT. APTTr activated partial thromboplastin time ratio, CRRT continuous renal replacement
therapy, HIT heparin-induced thrombocytopenia, INR international normalised ratio
Dickie et al. Critical Care  (2015) 19:376 Page 2 of 2The systemic effects of heparin are a potential
drawback of CRRT. We hope that our proposed algo-
rithm reduces this risk and allows effective and safe
anticoagulation.
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